Collegium Pharmaceutical, Inc. Long-Term Debt, Maturity, Year Two
Collegium Pharmaceutical, Inc. (COLL) had Long-Term Debt, Maturity, Year Two of $3.83 million as of 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2020-02-27
- 2019-12-31: Long-Term Debt, Maturity, Year Two $3.83M.
- 2019-09-30: Long-Term Debt, Maturity, Year Two $3.83M.
- 2019-06-30: Long-Term Debt, Maturity, Year Two $3.83M.
- 2019-03-31: Long-Term Debt, Maturity, Year Two $3.29M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2019-12-31 | $3.83M 10-K · filed 2020-02-27 |
| 2019-09-30 | $3.83M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $3.83M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $3.29M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $3.29M 10-K · filed 2019-02-27 |
| 2018-09-30 | $3.29M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $3.29M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $3.29M 10-Q · filed 2018-05-09 |
| 2016-12-31 | $1.48M 10-K · filed 2017-03-10 |
| 2015-12-31 | $2.67M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |